Filing Flows › Autolus Therapeutics (AUTL) › R&D spending
Autolus Therapeutics (AUTL) R&D spending by quarter
Autolus Therapeutics' R&D spending was $27.9M in Q2 2026 (second quarter 2026), +32% from Q1 2026. Over the last 6 quarters it ranged from $21.2M (Q1 2026) to $35.6M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $27.9M | +32% | +2% |
| Q1 2026 | $21.2M | -40% | -21% |
| Q4 2025 | $35.6M | +28% | — |
| Q3 2025 | $27.9M | +2% | — |
| Q2 2025 | $27.4M | +3% | — |
| Q1 2025 | $26.7M | — | — |
Q2 2026 at a glance
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Autolus Therapeutics' R&D spending?
Autolus Therapeutics' R&D spending was $27.9M in Q2 2026 (second quarter 2026), +32% from Q1 2026.
How has Autolus Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $21.2M (Q1 2026) to $35.6M (Q4 2025).